相关实验视频
Updated: Jun 27, 2026

07:46
Assessing Endothelial Vasodilator Function with the Endo-PAT 2000
Published on: October 16, 2010
内皮保护,AT1阻塞和胆固醇依赖的氧化应激:EPAS试验
Henning Morawietz1, Sandra Erbs, Jürgen Holtz
1Department of Vascular Endothelium and Microcirculation, Medical Faculty Carl Gustav Carus, University of Technology Dresden, Fetscherstr. 74, D-01307 Dresden, Germany. Henning.Morawietz@tu-dresden.de
Circulation
|July 6, 2006
概括
类药物和血管素1型 (AT1) 受体抑制剂改善了冠状动脉疾病患者的内皮功能和抗动脉样性基因表达. 联合治疗显示出最大的益处,增强内皮健康.
科学领域:
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 类药物和AT1受体抑制剂是已知的心血管疾病治疗方法.
- EPAS试验调查了它们对内皮细胞基因表达和功能的影响.
- 研究了冠状动脉疾病患者,以评估抗动脉样硬化作用.
研究的目的:
- 评估他类药物和AT1抑制剂的独立和联合作用.
- 评估治疗驱动的内皮基因表达的变化.
- 确定对冠状动脉疾病患者内皮功能的影响.
主要方法:
- 随机试验,包括60名冠状动脉疾病患者接受CABG手术.
- 四个治疗组:对照组,他类药物,AT1抑制剂和组合治疗.
- 在内部乳腺动脉活检中分析内皮表达率 (Q).
主要成果:
- 达丁类药物治疗显著增加了抗动脉样硬化内皮表达系数 (lnQ).
- AT1封锁显示了增加 lnQ 的趋势.
- 组合疗法进一步提高了InQ,并改善了动脉环中的内皮功能.
结论:
- 无论是他类药物治疗还是AT1抑制剂治疗,都能独立改善内皮细胞基因表达和功能.
- 结合疗法提供了增强的抗动脉样硬化益处.
- 这些发现支持使用组合疗法进行心血管保护.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Coronary Artery Disease I: Introduction
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Atherosclerosis I: Introduction
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

